Effects of Arsenic Trioxide on Proliferation, Paracrine and Migration of Cardiac Progenitor Cells

Wenya Ma,Liang Zhao,Kun Yin,Dan Feng,Fan Yang,Jing Liang,Hongyang Chen,Chongwei Bi,Xingda Li,Yang Wang,Benzhi Cai
DOI: https://doi.org/10.1016/j.ijcard.2014.11.028
IF: 4.039
2015-01-01
International Journal of Cardiology
Abstract:Arsenic trioxide (As2O3), a major effective constituent of arsenic which is an ancient traditional Chinese medicine. It was firstly used to cure chronic myelogenous leukemia (CML) [ [1] Murgo A.J. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist. 2001; 6: 22-28 Crossref PubMed Scopus (198) Google Scholar ]. Following researches found that As2O3 is an effective therapeutic agent for acute promyelocytic leukemia (APL) [ [2] Chen G.Q. et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996; 88: 1052-1061 PubMed Google Scholar ]. A lot of studies further showed that As2O3 also inhibits many other hematologic malignancies and solid tumors such as neuroblastoma, breast cancer, liver cancer, gastric cancer, lung cancer, esophageal cancer, cervical cancer and so on [ [3] Dilda P.J. Hogg P.J. Arsenical-based cancer drugs. Cancer. Treat. Rev. 2007; 33: 542-564 Abstract Full Text Full Text PDF PubMed Scopus (327) Google Scholar ]. The major therapeutic mechanism of As2O3 in APL is inducing apoptosis and inhibiting differentiation which depends on its concentration [ [4] Zhao W.L. et al. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies. Leuk. Lymphoma. 2001; 42: 1265-1273 Crossref PubMed Google Scholar ]. It has also been found that As2O3 (0.5 and 1 μM) can retard the cardiac differentiation of rat myoblast H9c2 cells through inhibiting PKCδ phosphorylation [ [5] Sumi D. Abe K. Himeno S. Arsenite retards the cardiac differentiation of rat cardiac myoblast H9c2 cells. Biochem. Biophys. Res. Commun. 2013; 436: 175-179 Crossref PubMed Scopus (14) Google Scholar ]. And higher dose of As2O3 (4 to 32 μM) significantly inhibited smooth muscle cell viability in a concentration-dependent manner [ [6] Li J.X. et al. Arsenic trioxide induces the apoptosis in vascular smooth muscle cells via increasing intracellular calcium and ROS formation. Mol. Biol. Rep. 2010; 37: 1569-1576 Crossref PubMed Scopus (41) Google Scholar ]. In further research, it was found that As2O3 can cause many side effects, especially cardiotoxicity [ [7] Hu J. et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2009; 106: 3342-3347 Crossref PubMed Scopus (359) Google Scholar ], mainly including rapid heart rate or prolonged QT interval [ [8] Zhou J. et al. The effect of arsenic trioxide on QT interval prolongation during APL therapy. Chin. Med. J. (Engl.). 2003; 116: 1764-1766 PubMed Google Scholar ]. The toxicity of As2O3 on hearts limits the application in clinics.
What problem does this paper attempt to address?